New drug cocktail shows promise against tough cancers

NCT ID NCT06783647

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called LBL-024 combined with other medicines in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or stop them from growing. About 230 adults aged 18-75 will take part, and the study will monitor side effects and how long any benefits last.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOUR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Affiliated Hospital of Guilin Medical University

    RECRUITING

    Guilin, Guangxi, 541001, China

  • Anhui Provincial Cancer Hospital

    RECRUITING

    Hefei, Anhui, 230031, China

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

  • Beijing Chest Hospital,Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 101100, China

  • First Hospital of Shanxi Medical University

    RECRUITING

    Taiyuan, Shanxi, 030012, China

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350014, China

  • Ganzhou People's Hospital

    RECRUITING

    Ganzhou, Jiangxi, 341006, China

  • Guangxi Medical University Cancer Hospital

    RECRUITING

    Nanning, Guangxi, 530021, China

  • Harbin Medical University Cancer Hospital

    RECRUITING

    Harbin, Heilongjiang, 150081, China

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, 450003, China

  • Jiangxi Cancer Hospital

    RECRUITING

    Nanchang, Jiangxi, 330029, China

  • Liaoning Cancer Hospital and Institute

    RECRUITING

    Shenyang, Liaoning, 110167, China

  • Mianyang Central Hospital

    RECRUITING

    Mianyang, Sichuan, 621000, China

  • Shandong Cancer Hospital

    RECRUITING

    Jinan, Shandong, 250117, China

  • Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, Sichuan, 610072, China

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

  • Taizhou Hospital of Zhejiang Province

    RECRUITING

    Taizhou, Zhejiang, 317000, China

  • The First Affiliated Hospital of Guangdong Pharmaceutical University

    RECRUITING

    Guangzhou, Guangdong, 510062, China

  • The First Affiliated Hospital of Henan University of Science & Technology

    RECRUITING

    Luoyang, Henan, 471023, China

  • The First Affiliated Hospital of Xiamen University

    RECRUITING

    Xiamen, Fujian, 361102, China

  • The Second Xiangya Hospital of Central South University

    RECRUITING

    Changsha, Hunan, 410011, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430022, China

  • Xiangyang Central Hospital

    RECRUITING

    Xiangyang, Hubei, 441106, China

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.